Targeting Rac and Cdc42 GEFs in Metastatic Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting Rac and Cdc42 GEFs in Metastatic Cancer

Published:2020-04-08 Issue: Volume:8 Page:
ISSN:2296-634X
Container-title:Frontiers in Cell and Developmental Biology
language:
Short-container-title:Front. Cell Dev. Biol.

Author:

Maldonado Maria del Mar,Medina Julia Isabel,Velazquez Luis,Dharmawardhane Suranganie

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

Frontiers Media SA

Subject

Cell Biology,Developmental Biology

Reference229 articles.

1. Novel p21-activated kinase 4 (PAK4) allosteric modulators overcome drug resistance and stemness in pancreatic ductal adenocarcinoma.;Aboukameel;Mol. Cancer Ther.,2017

2. Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides.;Adachi;Bioorganic Med. Chem.,2017

3. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation.;Aghazadeh;Cell,2000

4. Inhibition of Cdc42–intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.;Aguilar;Cancer Biol. Ther.,2019

5. VAV3 mediates resistance to breast cancer endocrine therapy.;Aguilar;Breast Cancer Res.,2014

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic profiling of ZCL-278, a cdc42 inhibitor, and its effectiveness against chronic kidney disease;Biomedicine & Pharmacotherapy;2024-10

2. Targeting guanine nucleotide exchange factors for novel cancer drug discovery;Expert Opinion on Drug Discovery;2024-06-17

3. Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy;Journal of Medicinal Chemistry;2024-06-12

4. The role of the Rho family small GTPases in regulation of normal and pathological processes;Цитология;2024-06-05

5. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer;Translational Oncology;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3